Akamai Technologies, Inc. (AKAM)
| Previous Close | 102.46 |
| Open | 94.20 |
| Bid | 91.21 x 100 |
| Ask | 91.42 x 500 |
| Day's Range | 90.89 - 94.82 |
| 52 Week Range | 84.19 - 129.17 |
| Volume | |
| Avg. Volume | 1,739,575 |
| Market Cap | 13.996B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 25.95 |
| EPS (TTM) | 3.52 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 126.50 |
Barrons.comThese Stocks Are Moving the Most Today: Novavax, Akamai, Sweetgreen, Taiwan Semi, Moderna, Gen Digital, JFrog, SoundHound, and More
Novavax stock surges after the vaccine maker signs a $1.2 billion licensing deal with France’s Sanofi, guidance from Akamai Technologies misses estimates, and Sweetgreen soars after the salad chain boosts its full-year revenue outlook.
StockStoryWhy Akamai (AKAM) Shares Are Sliding Today
Shares of web content delivery and security company Akamai (NASDAQ:AKAM) fell 11.2% in the morning session after the company reported first-quarter earnings results. Although its EPS beat Wall Street's estimates, its full-year revenue guidance missed analysts' expectations, sending the stock down. Company outlooks have been the big focus this earnings season. On the bright side, the Board authorized a new three-year, $2.0 billion share repurchase program. Overall, the results could have been bet
- GuruFocus.com
Akamai Technologies Inc (AKAM) Surpasses Analyst EPS Estimates in Q1 2024
Robust Growth in Security and Compute Solutions Drives Performance
